Business Context and Reporting Period
Company: Nanophase Technologies Corporation (NANX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Nanophase develops and manufactures engineered nanomaterials for diverse markets including sunscreens, personal care, architectural coatings, and semiconductor polishing. The company has shifted strategy from a pure materials provider to a "solutions provider," integrating products directly into customer applications. In early 2010, the company launched its first direct-to-user product line, NanoUltra, for architectural window cleaning.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $6,320,326 | $10,213,817 |
| Product Revenue | $5,937,100 | $9,744,759 |
| Gross Profit | $951,607 | $2,712,349 |
| Gross Margin | 15.1% | 26.6% |
| Net Loss | $(4,889,343) | $(6,437,847) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.30) |
| Cash and Cash Equivalents | $3,899,393 | $723,069 |
| Total Investments (Current) | $3,594,604 | $6,908,888 |
| Long-Term Debt | $0 | $1,570,346 |
| Net Cash Used in Operating Activities | $(3,614,979) | $(2,560,783) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 38% ($3.9 million) compared to 2008. This was primarily driven by decreased sales to key customers due to aggressive inventory reduction programs and a global economic recession.
- Cost Reductions: Cost of revenue decreased to $5.4 million (from $7.5 million) due to lower volume and manufacturing efficiencies. Selling, general, and administrative (SG&A) expenses dropped significantly to $3.9 million (from $5.4 million) following restructuring efforts, including the elimination of 12 positions and executive departures.
- Debt Elimination: The company repaid its entire $1.6 million debt obligation to BYK-Chemie in July 2009, resulting in a debt-free balance sheet as of year-end.
- Investment Portfolio: The company held Auction Rate Securities (ARS) valued at $3.56 million (net of impairment) at year-end. A $2 million ARS was sold in October 2009 for a realized loss of $60,000. A subsequent event in March 2010 resolved an arbitration with Credit Suisse, agreeing to purchase the remaining ARS holdings for $4 million, resulting in a $440,000 recovery of expense recorded in 2009.
- Severance Charges: The company incurred $794,069 in severance charges in 2009 (compared to $1.6 million in 2008) related to executive resignations and operational reorganization.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue focusing on reducing controllable variable manufacturing costs. While absolute dollar gross margin growth is expected through 2010, it is dependent on revenue volume and mix. The company anticipates that cash on hand, including the proceeds from the ARS sale, will be adequate to fund operations through 2010.
- Capital Expenditures: Projected capital spending for 2010 is approximately $300,000.
- Customer Concentration Risk: Revenue is highly concentrated. In 2009, three customers accounted for approximately 81% of total revenue (BASF at 63%, an architectural coatings customer at 13%, and a medical diagnostics customer at 5%).
- Covenant Risks: The supply agreement with BASF contains financial covenants requiring a minimum of $2 million in cash and investments. Failure to meet these could trigger a transfer of technology and equipment to BASF. The company believes its current liquidity position avoids this trigger.
- Market Risk: The company faces risks related to the acceptance of nanomaterials in new markets, competition from larger chemical companies, and the potential expiration of net operating loss carryforwards (approximately $80 million).
- Stock Listing: As of December 2009, the company was not in compliance with NASDAQ listing rules due to a closing bid price below $1.00 for 30 consecutive days. It has a 180-day grace period to regain compliance.
Investor Verification Checklist
- Liquidity vs. Covenants: Verify that the company maintains the $2 million minimum cash/investment threshold required by the BASF supply agreement to prevent technology transfer.
- Customer Concentration: Assess the stability of the top three customers (BASF, architectural coatings, medical diagnostics) which represent over 80% of revenue.
- ARS Resolution: Confirm the finalization of the Credit Suisse settlement and the receipt of the $4 million proceeds for the remaining Auction Rate Securities.
- NASDAQ Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement within the 180-day grace period ending June 16, 2010.
- Revenue Recovery: Evaluate the success of the new "customer direct" sales model and the NanoUltra product line in offsetting the decline in partner-driven sales.